Trials

  • CERC Trial

    EuroNetrod HTN OFF-Med

    -

    EuroNetrod HTN OFF-Med Study is a multi-center blinded, 3-arm randomized (2:1:1) controlled investigation that aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes...

  • CERC Trial

    EVERGREEN

    -

    Evaluation of the Valiant Captivia Physician fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies (EVERGREEN) EVERGREEN study is a prospective, multi-center, multinational, single arm study. The objective is to evaluate the safety and effectiveness of Valiant...

  • Image

    FIH IPERF-01

    -

    IPERF-01 is a prospective, interventional, single arm, longitudinal, monocentric clinical investigation. The objective is to assess the safety of the iPerf femoral arterial cannula in patients undergoing a planned cardiac surgery requiring the use of an extracorporeal circulation via a femoral...

  • CERC Trial

    GLYCAR

    -

    GLYCAR STUDY is a Post Market Multicenter clinical investigation of GLYCAR Bovine pericardial patch with EnCap™ Technology in cardiac and vascular repair or reconstruction surgery. The main objective of this study is to collect real-world, long term clinical data in 100 adult and pediatric patients...

  • CERC Trial

    ILLUMINA

    -

    The Illumina study has been designed to evaluate the efficacy and safety of the new self-expanding polymer free drug eluting stent – NiTiDES – for SFA manufactured by CID S.p.A. member of Alvimedica group. Currently this device represents the first attempt to embed a controlled and targeted drug...

  • CERC Trial

    INFINITY-SWEDEHEART

    -

    The INFINITY-SWEDEHEART trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor: Resolute Onyx) The INFINITY-SWEDEHEART study will evaluate the safety and effectiveness of the DynamX Bioadaptor compared...

  • CERC Trial

    IonMAN

    -

    This is a prospective, multi-center, single-arm, open-label, First in Human clinical trial. Clinical follow-up for all patients will be performed at 30 days, 6 months, 1 year after the procedure, and then until 5 years. The enrollment was finalized in June 2023 with a total of 60 subjects were...

  • CERC Trial

    KISS

    -

    KISS study is an investigator-initiated, multi-centre, prospective, randomized (1:1), parallel, two-arm, non-inferiority trial aiming to compare two bifurcation percutaneous coronary intervention (PCI) procedures for side branch protection. In the treatment of bifurcation lesion, the role of side...

  • CERC Trial

    LANDMARK

    -

    Landmark Trial is a prospective, randomized, multinational, multicentric, open-label non-inferiority trial of approximately 768 subjects (384:384, Myval THV Series vs. Contemporary Valves) with severe symptomatic native aortic valve stenosis via transfemoral approach. ClincalTrials.gov ID...

  • CERC Trial

    LEADERS FREE

    -

    LEADERS-FREE is a randomized double-blinded trial which was designed to assess the combination of a short course (1 month) of DAPT with either the BioFreedom DCS (drug-coated stent) or the Gazelle BMS in patients with at least one of several criteria for an increased bleeding risk: advanced age...